WO2003028757A1 - Nouvelle methode pour induire des lymphocytes t specifiques d'antigenes - Google Patents

Nouvelle methode pour induire des lymphocytes t specifiques d'antigenes Download PDF

Info

Publication number
WO2003028757A1
WO2003028757A1 PCT/JP2002/009993 JP0209993W WO03028757A1 WO 2003028757 A1 WO2003028757 A1 WO 2003028757A1 JP 0209993 W JP0209993 W JP 0209993W WO 03028757 A1 WO03028757 A1 WO 03028757A1
Authority
WO
WIPO (PCT)
Prior art keywords
specific
cells
novel method
inducing antigen
antigen
Prior art date
Application number
PCT/JP2002/009993
Other languages
English (en)
French (fr)
Inventor
Haruo Sugiyama
Original Assignee
Haruo Sugiyama
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Haruo Sugiyama filed Critical Haruo Sugiyama
Priority to JP2003532087A priority Critical patent/JP5230891B2/ja
Priority to EP02800016A priority patent/EP1447091A4/en
Priority to US10/490,873 priority patent/US8735357B2/en
Publication of WO2003028757A1 publication Critical patent/WO2003028757A1/ja

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55522—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55583—Polysaccharides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55588—Adjuvants of undefined constitution
    • A61K2039/55594—Adjuvants of undefined constitution from bacteria

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Cell Biology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
PCT/JP2002/009993 2001-09-28 2002-09-27 Nouvelle methode pour induire des lymphocytes t specifiques d'antigenes WO2003028757A1 (fr)

Priority Applications (3)

Application Number Priority Date Filing Date Title
JP2003532087A JP5230891B2 (ja) 2001-09-28 2002-09-27 抗原特異的ｔ細胞の新規な誘導方法
EP02800016A EP1447091A4 (en) 2001-09-28 2002-09-27 NEW METHOD FOR INDUCTION OF ANTIGEN SPECIFIC T CELLS
US10/490,873 US8735357B2 (en) 2001-09-28 2002-09-27 Method of inducing antigen-specific T cells

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2001-301206 2001-09-28
JP2001301206 2001-09-28

Publications (1)

Publication Number Publication Date
WO2003028757A1 true WO2003028757A1 (fr) 2003-04-10

Family

ID=19121654

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2002/009993 WO2003028757A1 (fr) 2001-09-28 2002-09-27 Nouvelle methode pour induire des lymphocytes t specifiques d'antigenes

Country Status (4)

Country Link
US (1) US8735357B2 (ja)
EP (1) EP1447091A4 (ja)
JP (2) JP5230891B2 (ja)
WO (1) WO2003028757A1 (ja)

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005001117A1 (ja) * 2003-06-27 2005-01-06 Haruo Sugiyama Ｗｔ１ワクチン適応患者の選択方法
JP2009286792A (ja) * 2005-11-30 2009-12-10 International Institute Of Cancer Immunology Inc 新規ペプチド化合物
JP2013116891A (ja) * 2011-11-01 2013-06-13 Nagoya Univ 髄膜腫治療用医薬組成物
JP2014510070A (ja) * 2011-02-28 2014-04-24 カディラ ファーマシューティカルズ リミテッド 治療用癌ワクチン
US9803246B2 (en) 2011-06-28 2017-10-31 International Institute Of Cancer Immunology, Inc. Receptor gene for peptide cancer antigen-specific T cell
US10093977B2 (en) 2007-03-05 2018-10-09 International Institute Of Cancer Immunology, Inc. Cancer antigen-specific T-cell receptor gene, peptide encoded by the gene, and use of them
WO2018219299A1 (en) * 2017-05-31 2018-12-06 Carsgen Therapeutics Co., Ltd. Compositions and methods of cellular immunotherapy

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1560078B (zh) * 1998-07-31 2011-06-22 株式会社国际癌症免疫研究所 基于癌抑制基因wt1的产物的癌抗原
CA2440303C (en) * 2001-03-22 2013-03-19 Haruo Sugiyama Wt1 modified peptide
JPWO2003028758A1 (ja) * 2001-09-28 2005-01-13 治夫 杉山 抗原特異的ｔ細胞の誘導方法
US8735357B2 (en) 2001-09-28 2014-05-27 International Institute Of Cancer Immunology, Inc. Method of inducing antigen-specific T cells
ATE466084T1 (de) * 2002-06-12 2010-05-15 Int Inst Cancer Immunology Inc Hla-a24-restringiertes krebsantigenpeptid
ES2538486T3 (es) * 2002-09-12 2015-06-22 International Institute Of Cancer Immunology, Inc. Preparación de péptidos antigénicos contra el cáncer
ATE442378T1 (de) * 2002-09-20 2009-09-15 Int Inst Cancer Immunology Inc Substituierte wt1-peptide
US20060217297A1 (en) * 2003-01-15 2006-09-28 Haruo Sugiyama Dimerized peptide
KR101213015B1 (ko) 2003-11-05 2012-12-26 인터내셔널 인스티튜트 오브 캔서 이무놀로지 인코퍼레이티드 Ｗｔ１ 로부터 유도된 ｈｌａ-ｄｒ 결합성 항원 펩티드
SI1731605T1 (sl) * 2004-03-31 2010-07-30 Internat Inst Of Cancer Immunolog Inc Peptidi antigena karcinoma izvedeni iz WT1
AU2006304573B2 (en) 2005-10-17 2012-05-24 Sloan Kettering Institute For Cancer Research WT1 HLA class II-binding peptides and compositions and methods comprising same
EP3117836A1 (en) 2006-04-10 2017-01-18 Sloan Kettering Institute For Cancer Research Immunogenic wt-1 peptides and uses thereof
CN104774910B (zh) 2007-02-27 2018-04-10 株式会社癌免疫研究所 活化辅助t细胞的方法以及用于该方法的组合物
ITTO20070401A1 (it) * 2007-06-07 2008-12-08 Univ Degli Studi Torino Vaccino anti-tumorale
ES2849187T3 (es) 2010-10-05 2021-08-16 Int Inst Cancer Immunology Inc Método para activar células T auxiliares
JP6282598B2 (ja) 2012-01-13 2018-02-21 メモリアル スローン ケタリング キャンサー センター 免疫原性ｗｔ１ペプチド及びその使用方法
JP6530192B2 (ja) 2012-12-17 2019-06-12 大塚製薬株式会社 ヘルパーｔ細胞の活性化方法
CN116789792A (zh) 2013-01-15 2023-09-22 纪念斯隆凯特林癌症中心 免疫原性wt-1肽和其使用方法
US10815273B2 (en) 2013-01-15 2020-10-27 Memorial Sloan Kettering Cancer Center Immunogenic WT-1 peptides and methods of use thereof
KR101715468B1 (ko) * 2015-03-31 2017-03-13 서울대학교산학협력단 활성화 b 세포를 이용한 항원 특이적 세포 독성 t 세포 제조 방법 및 그 용도

Citations (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6122018A (ja) * 1984-07-06 1986-01-30 Green Cross Corp:The 癌免疫療法増強剤
WO1995016464A1 (en) * 1993-12-14 1995-06-22 Johns Hopkins University School Of Medicine Controlled release of pharmaceutically active substances for immunotherapy
WO1996002555A1 (en) * 1994-07-15 1996-02-01 The University Of Iowa Research Foundation Immunomodulatory oligonucleotides
WO1999044634A1 (en) * 1998-03-05 1999-09-10 The Medical College Of Ohio Il-12 stimulation of neonatal immunity
WO2000018795A2 (en) * 1998-09-30 2000-04-06 Corixa Corporation Compositions and methods for wt1 specific immunotherapy
WO2000041463A2 (en) * 1999-01-12 2000-07-20 Smithkline Beecham Biologicals S.A. Combination of hepatitis b vaccine with antiviral agents
WO2000044349A1 (en) * 1999-01-27 2000-08-03 Idea Ag Non-invasive vaccination through the skin
JP2001089389A (ja) * 1999-07-22 2001-04-03 Sumitomo Pharmaceut Co Ltd 抗原特異的ｔ細胞の誘導剤
WO2001062920A2 (en) * 2000-02-22 2001-08-30 Corixa Corporation Compositions and methods for diagnosis and therapy of malignant mesothelioma
WO2002079253A1 (fr) * 2001-03-22 2002-10-10 Haruo Sugiyama Peptide modifie wt1

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4820514A (en) * 1985-12-30 1989-04-11 Texas A&M University System Low dosage of interferon to enhance vaccine efficiency
JP4789095B2 (ja) 1997-07-16 2011-10-05 治夫 杉山 ウイルムス腫瘍遺伝子（ｗｔ１）に対する発現阻害物質を含んで成る固形腫瘍治療剤
IT246029Y1 (it) * 1998-02-26 2002-03-26 Pool S R L Apparecchio telefonico ricetrasmittente del tipo a rete mobile
CN1560078B (zh) 1998-07-31 2011-06-22 株式会社国际癌症免疫研究所 基于癌抑制基因wt1的产物的癌抗原
GB9823897D0 (en) 1998-11-02 1998-12-30 Imp College Innovations Ltd Immunotherapeutic methods and molecules
CA2394597A1 (en) 2000-01-05 2001-07-12 Aventis Pasteur Limited Enhancing the immune response to an antigen by presensitizing with an inducing agent prior to immunizing with the inducing agent and the antigen
US8735357B2 (en) 2001-09-28 2014-05-27 International Institute Of Cancer Immunology, Inc. Method of inducing antigen-specific T cells
JPWO2003028758A1 (ja) 2001-09-28 2005-01-13 治夫 杉山 抗原特異的ｔ細胞の誘導方法
ATE466084T1 (de) 2002-06-12 2010-05-15 Int Inst Cancer Immunology Inc Hla-a24-restringiertes krebsantigenpeptid
KR101213015B1 (ko) 2003-11-05 2012-12-26 인터내셔널 인스티튜트 오브 캔서 이무놀로지 인코퍼레이티드 Ｗｔ１ 로부터 유도된 ｈｌａ-ｄｒ 결합성 항원 펩티드
SI1731605T1 (sl) 2004-03-31 2010-07-30 Internat Inst Of Cancer Immunolog Inc Peptidi antigena karcinoma izvedeni iz WT1

Patent Citations (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6122018A (ja) * 1984-07-06 1986-01-30 Green Cross Corp:The 癌免疫療法増強剤
WO1995016464A1 (en) * 1993-12-14 1995-06-22 Johns Hopkins University School Of Medicine Controlled release of pharmaceutically active substances for immunotherapy
WO1996002555A1 (en) * 1994-07-15 1996-02-01 The University Of Iowa Research Foundation Immunomodulatory oligonucleotides
WO1999044634A1 (en) * 1998-03-05 1999-09-10 The Medical College Of Ohio Il-12 stimulation of neonatal immunity
WO2000018795A2 (en) * 1998-09-30 2000-04-06 Corixa Corporation Compositions and methods for wt1 specific immunotherapy
WO2000041463A2 (en) * 1999-01-12 2000-07-20 Smithkline Beecham Biologicals S.A. Combination of hepatitis b vaccine with antiviral agents
WO2000044349A1 (en) * 1999-01-27 2000-08-03 Idea Ag Non-invasive vaccination through the skin
JP2001089389A (ja) * 1999-07-22 2001-04-03 Sumitomo Pharmaceut Co Ltd 抗原特異的ｔ細胞の誘導剤
WO2001062920A2 (en) * 2000-02-22 2001-08-30 Corixa Corporation Compositions and methods for diagnosis and therapy of malignant mesothelioma
WO2002079253A1 (fr) * 2001-03-22 2002-10-10 Haruo Sugiyama Peptide modifie wt1

Non-Patent Citations (10)

* Cited by examiner, † Cited by third party
Title
DATABASE CA [online] 2002, TSUBOI A. ET AL.: "Enhanced induction of human WT1-specific cytotoxic T lymphocytes with a 9-mer WT1 peptide modified at HLA-A*2402-binding residues", XP003031710, Database accession no. 2002:880632 *
HARUO SUGIYAMA: "Saibo shuki to gan - WT1 tanpaku o hyoteki ni shita gan no men'eki ryoho -", BIOTHERAPY, vol. 14, no. 8, 2000, pages 789 - 795, XP002963476 *
ICHIRO HIGASHI: "BRM to shite no saikin kintai seibun", BIOMEDICINE & THERAPEUTICS, vol. 20, no. 1, 1988, pages 21 - 26, XP002963480 *
LIN R. ET AL.: "Present status of the use of cytokines as adjuvants with vaccines to protect against infectious diseases", CLIN. INFECT. DIS., vol. 21, no. 6, December 1995 (1995-12-01), pages 1439 - 1449, XP000576631 *
OKA Y. ET AL.: "Cancer immunotherapy targeting wilms' tumor gene WT1 product", J. IMMUNOL., vol. 164, no. 4, 15 February 2000 (2000-02-15), pages 1873 - 1880, XP000890067 *
See also references of EP1447091A4 *
SUGIYAMA H. ET AL.: "Wilms' tumor gene WT1: its oncogenic function and clinical application", INT. J. HEMATOL., vol. 73, February 2001 (2001-02-01), pages 177 - 187, XP002963478 *
TSUBOI A. ET AL.: "Enhanced induction of human WT1-specific cytotoxic T lymphocytes with a 9-mer WT1 peptide modified at HLA-A*2402-binding residues", CANCER IMMUNOL. IMMUNOTHER., vol. 51, no. 11-12, December 2002 (2002-12-01), pages 614 - 620 *
YOSHIHIRO OKA ET AL.: "3. Men'eki ryoho 2) WT1 o hyoteki to shita hakketsubyo ni taisuru tokuiteki men'eki ryoho", HEMATOLOGY FRONTIER, vol. 10, no. 8, 2000, pages 1017 - 1023, XP002963477 *
YOSHIRO TANIO ET AL.: "Men'eki kyoka busshitsu", JAPANESE JOURNAL OF CANCER AND CHEMOTHERAPY, vol. 7, no. 9, 1980, pages 1710 - 1718, XP002963479 *

Cited By (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005001117A1 (ja) * 2003-06-27 2005-01-06 Haruo Sugiyama Ｗｔ１ワクチン適応患者の選択方法
US10500257B2 (en) 2003-06-27 2019-12-10 International Institute Of Cancer Immunology, Inc. Method of selecting WT1 vaccine adaptive patient
JP2009286792A (ja) * 2005-11-30 2009-12-10 International Institute Of Cancer Immunology Inc 新規ペプチド化合物
JP2012158597A (ja) * 2005-11-30 2012-08-23 International Institute Of Cancer Immunology Inc 新規ペプチド化合物
KR101385805B1 (ko) 2005-11-30 2014-04-16 인터내셔널 인스티튜트 오브 캔서 이무놀로지 인코퍼레이티드 신규 펩티드 화합물
JP2014080435A (ja) * 2005-11-30 2014-05-08 International Institute Of Cancer Immunology Inc 新規ペプチド化合物
US10093977B2 (en) 2007-03-05 2018-10-09 International Institute Of Cancer Immunology, Inc. Cancer antigen-specific T-cell receptor gene, peptide encoded by the gene, and use of them
US10669584B2 (en) 2007-03-05 2020-06-02 International Institute Of Cancer Immunology, Inc. Cancer antigen-specific T-cell receptor gene, peptide encoded by the gene, and use of them
JP2014510070A (ja) * 2011-02-28 2014-04-24 カディラ ファーマシューティカルズ リミテッド 治療用癌ワクチン
US10648036B2 (en) 2011-06-28 2020-05-12 International Institute Of Cancer Immunology, Inc. Receptor gene for peptide cancer antigen-specific T cell
US9803246B2 (en) 2011-06-28 2017-10-31 International Institute Of Cancer Immunology, Inc. Receptor gene for peptide cancer antigen-specific T cell
JP2013116891A (ja) * 2011-11-01 2013-06-13 Nagoya Univ 髄膜腫治療用医薬組成物
WO2018219299A1 (en) * 2017-05-31 2018-12-06 Carsgen Therapeutics Co., Ltd. Compositions and methods of cellular immunotherapy
US11419895B2 (en) 2017-05-31 2022-08-23 Crage Medical Co., Limited Compositions and methods of cellular immunotherapy

Also Published As

Publication number Publication date
JPWO2003028757A1 (ja) 2005-01-13
EP1447091A1 (en) 2004-08-18
US20040247609A1 (en) 2004-12-09
JP5230891B2 (ja) 2013-07-10
JP2010248204A (ja) 2010-11-04
US8735357B2 (en) 2014-05-27
EP1447091A4 (en) 2008-02-13

Similar Documents

Publication Publication Date Title
WO2003028757A1 (fr) Nouvelle methode pour induire des lymphocytes t specifiques d'antigenes
WO2003028758A1 (fr) Nouvelle methode d'induction de lymphocytes t specifiques d'un antigene
DE60229979D1 (ja)
WO2003000343A3 (en) Administration of phosphodiesterase inhibitors for the treatment of premature ejaculation
WO2003002136A3 (en) Stable formulation of modified glp-1
AU7315496A (en) Delivery of biologically active polypeptides
AU3121497A (en) Methods of treating type i hypersensitivity using monophosphoryl lipid
AU2002231654A1 (en) Pharmaceutical paste comprising an acid-labile active ingredient
AU2084801A (en) Antiviral medication
WO2002088328A3 (en) Method for generating highly active human dendritic cells from monocytes
WO2002085311A3 (en) Hcg formulation
EP2502998A3 (en) Recombinant toxin A/ToxinB vaccine against clostridium difficile
ES2168457T3 (es) Composiciones farmaceuticas que comprenden una superoxido dismutasa.
MY136546A (en) A pharmaceutical component based on human parathyroid harmone and a pharmaceutical composition for intranasal administration comprising the component
AU1041397A (en) Antigenic protein originating in malassezia
MXPA02011533A (es) Nuevas formulaciones de alfa-2,4-disulfofenil-n-terc-butilnitrona.
CA2420640A1 (en) Combination preparations of 3-n-formyl hydroxy amino propyl phosphonic acid derivatives or 3-n-acetyl hydroxy amino propyl phosphonic acid derivatives together with special pharmaceutical active ingredients
WO2003061557A3 (en) Levothyroxine pharmaceutical compositions, methods of making and methods of administration
EP1583545A4 (en) PHARMACEUTICAL COMPOSITION FOR IMPROVED ADMINISTRATION OF PEPTIDES OF HIV GP41 AND ITS THERAPEUTIC USE
WO2003075849A3 (en) Composition and method for enhancing immune response
PT1144420E (pt) Fosfatidilinositois sulfatados a sua preparacao e a sua utilizacao
AU2001289762A1 (en) Pharmaceutical extemporary compositions
WO2004081031A3 (en) Thiol-mediated drug attachment to targeting peptides
EP0952771A4 (en) SAPONIN COMPOSITIONS AND THEIR USE
AU2229997A (en) Pharmaceutical compositions comprising natural human alpha-interferon

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BY BZ CA CH CN CO CR CU CZ DE DM DZ EC EE ES FI GB GD GE GH HR HU ID IL IN IS JP KE KG KR KZ LK LR LS LT LU LV MA MD MG MK MW MX MZ NO NZ OM PH PL PT RO SD SE SG SI SK SL TJ TM TN TR TT UA UG US UZ VC VN YU ZA ZM

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW MZ SD SL SZ UG ZM ZW AM AZ BY KG KZ RU TJ TM AT BE BG CH CY CZ DK EE ES FI FR GB GR IE IT LU MC PT SE SK TR BF BJ CF CG CI GA GN GQ GW ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2003532087

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 2002800016

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 10490873

Country of ref document: US

WWP Wipo information: published in national office

Ref document number: 2002800016

Country of ref document: EP